Cellemedy-VEGF

Cellemedy-VEGF is an investigational multi-specific therapeutic candidate being developed by Cellemedy using its proprietary **T-sphaera™** platform. The T-sphaera technology utilizes a 24-subunit ferritin nanocage to display multiple binding moieties, such as antibody fragments, creating a spherical protein nanoparticle (immunoferritin). This specific program is designed to simultaneously target **Vascular Endothelial Growth Factor (VEGF)** and the **PD-1/PD-L1** immune checkpoint pathway. By combining anti-angiogenic activity with immune checkpoint inhibition, the drug aims to enhance T-cell infiltration and overcome immune resistance within the tumor microenvironment. The ferritin-based architecture is intended to provide improved structural stability and more effective biodistribution compared to conventional bispecific antibodies, allowing the drug to remain widely dispersed in the tumor microenvironment.

Other names

VEGF ProgramPD-(L)1 x VEGF TSMTT-sphaera VEGF